EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye. The code, J7314, will become effective one quarter early on October 1, 2019.
“We are very pleased with CMS’s decision to begin issuing certain J-codes quarterly, versus the prior policy of annually, which has now resulted in Yutiq receiving its specific and permanent code effective October 1, 2019,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “This is one quarter earlier than under the prior CMS policy. Yutiq reimbursement is currently being processed through the utilization of either a miscellaneous or a shared billing code, and payor support for reimbursement of Yutiq has been positive. The October 1 effective date of a permanent J-code specific to Yutiq will allow treating physicians, insurers and patients to benefit sooner from a more streamlined approval and reimbursement process.”
“This key market access milestone is another positive step forward in our ongoing U.S. commercial launch of Yutiq for this potentially blinding ocular disease,” Ms. Lurker said.